News

The Quad contains four Gilead compounds in a complete once-daily, single-tablet regimen which includes elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. The MAA for the Quad is supported

As per the agreement, Hua will receive the full preclinical and clinical documentation for Roche’s GKA program, drug product API for RO5305552, and rights to potential back-up compounds.

Both the companies collaborate on ProteoTech’s small molecule technology platform against misfolded proteins to work on its alpha-synuclein therapeutic program. Michael J. Fox Foundation for Parkinson’s Research has

The new patent is estimated to provide protection until March 2027. Marshall CEO and president Daniel Gold said the patent represents another important milestone in their efforts to

Pfizer is responsible for the clinical development, manufacturing, and commercialization of the product in the licensed territory, as well as certain non-exclusive territories outside of North America. As

Edarbyclor is a once-daily fixed-dose combination regimen of azilsartan medoxomil and diuretic chlorthalidone. The recommended starting dose of Edarbyclor is 40/12.5 mg and the maximum dose is 40/25

Tofacitinib an investigational drug is an oral JAK inhibitor. The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action date in August 2012 for the

Starpharma and Eli Lilly are working on many projects for the improvement in delivery of small molecule and protein-based pharmaceuticals, with the help of dendrimer technology by Starpharma.

The first randomized double-blind placebo-controlled Phase III Altitude study included patients with type 2 diabetes and renal impairment, to evaluate Rasilez/Tekturna for more than one year in a